Your browser doesn't support javascript.
The relationship between asthma, eosinophilia, and outcomes in coronavirus disease 2019 infection.
Ho, Kam Sing; Howell, Daniel; Rogers, Linda; Narasimhan, Bharat; Verma, Hannah; Steiger, David.
  • Ho KS; Department of Medicine, Mount Sinai Morningside & Mount Sinai West Hospitals, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: Kam.ho@mountsinai.org.
  • Howell D; Department of Pulmonary & Critical Care, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Rogers L; Department of Pulmonary & Critical Care, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Narasimhan B; Department of Medicine, Mount Sinai Morningside & Mount Sinai West Hospitals, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Verma H; Department of Political Science, Yale University, New Haven, Connecticut.
  • Steiger D; Department of Pulmonary & Critical Care, Mount Sinai Beth Israel, Mount Sinai Morningside & Mount Sinai West Hospitals, Icahn School of Medicine at Mount Sinai, New York, New York.
Ann Allergy Asthma Immunol ; 127(1): 42-48, 2021 07.
Article in English | MEDLINE | ID: covidwho-1155397
ABSTRACT

BACKGROUND:

The impact of asthma diagnosis and asthma endotype on outcomes from coronavirus disease 2019 (COVID-19) infection remains unclear.

OBJECTIVE:

To describe the association between asthma diagnosis and endotype and clinical outcomes among patients diagnosed as having COVID-19 infection.

METHODS:

Retrospective multicenter cohort study of outpatients and inpatients presenting to 6 hospitals in the Mount Sinai Health System New York metropolitan region between March 7, 2020, and June 7, 2020, with COVID-19 infection, with and without a history of asthma. The primary outcome evaluated was in-hospital mortality. Secondary outcomes included hospitalization, intensive care unit admission, mechanical ventilation, and hospital length of stay. The outcomes were compared in patients with or without asthma using a multivariate Cox regression model. The outcomes stratified by blood eosinophilia count were also evaluated.

RESULTS:

Of 10,523 patients diagnosed as having COVID-19 infection, 4902 were hospitalized and 468 had a diagnosis of asthma (4.4%). When adjusted for COVID-19 disease severity, comorbidities, and concurrent therapies, patients with asthma had a lower mortality (adjusted odds ratio [OR], 0.64 (0.53-0.77); P < .001) and a lower rate of hospitalization and intensive care unit admission (OR, 0.43 (0.28-0.64); P < .001 and OR, 0.51 (0.41-0.64); P < .001, respectively). Those with blood eosinophils greater than or equal to 200 cells/µL, both with and without asthma, had lower mortality.

CONCLUSION:

Patients with asthma may be at a reduced risk of poor outcomes from COVID-19 infection. Eosinophilia, both in those with and without asthma, may be associated with reduced mortality risk.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Asthma / Eosinophilia / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: North America Language: English Journal: Ann Allergy Asthma Immunol Journal subject: Allergy and Immunology Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Asthma / Eosinophilia / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: North America Language: English Journal: Ann Allergy Asthma Immunol Journal subject: Allergy and Immunology Year: 2021 Document Type: Article